- BridgeBio adds $1B as it prepares three more drug launchesBridgeBio Pharma has reloaded with about $1 billion in a preferred equity deal to bolster its reserves ahead of three potential drug launches over the next year. The California biotech, which for y…Endpoints · 27d ago↗ source
- Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M dealThe purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.BioPharma Dive · 27d ago↗ source
- 92Bio revives a T cell engager it had transferred to AmgenA small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug…Endpoints